LEXICON'S SOTAGLIFLOZIN WINS FDA NOD FOR HEART FAILURE; UP 11% AFTER HOURS

• The US FDA has approved Lexicon Pharmaceuticals' Inpefa (sotagliflozin) to cut the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.
• The oral pill is intended for those with heart failure, type 2 diabetes, chronic kidney disease, or other CV disease risk factors.
• Lexicon (NASDAQ:LXRX) shares are up ~11% in after-hours trading Friday.
• The company expects Inpefa to be available by the end of June.
• The approval was supported by two double-blind, placebo-controlled trials. One of them showed that Inpefa reduced the risk of the composite of hospitalizations for heart failure, urgent visits for heart failure, and CV death by 33% compared to placebo.

More on Lexicon Pharmaceuticals

• Lexicon Pharmaceuticals: May 27 PDUFA Date For Heart Failure Drug Looks Crucial

• Lexicon Pharma: Advancing A Worthwhile Pipeline But Commercialization Remains A Key Risk

Now read: Mirati tumbles after study failure for cancer drug; Oppenheimer upgrades

2023-05-26T20:39:54Z dg43tfdfdgfd